Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Neuropharmacology
2019 Jan 01;144:172-183. doi: 10.1016/j.neuropharm.2018.10.032.
Show Gene links
Show Anatomy links
Amphetamine enantiomers inhibit homomeric α7 nicotinic receptor through a competitive mechanism and within the intoxication levels in humans.
Garton DR
,
Ross SG
,
Maldonado-Hernández R
,
Quick M
,
Lasalde-Dominicci JA
,
Lizardi-Ortiz JE
.
???displayArticle.abstract???
Amphetamine-type stimulants (ATS) are the second most consumed illicit drug worldwide and lack good treatments for associated substance use disorders, lagging behind other addictive drugs. For this reason, a deeper understanding of the pharmacodynamics of ATS is required. The present study seeks to determine amphetamine (AMPH) enantiomers' effects on the homomeric α7 nicotinic acetylcholine receptor (α7 nAChR). Here we have shown that AMPH enantiomers bind to the α7 nAChR and competitively inhibit acetylcholine responses. Our in silico docking analysis suggests that AMPH binds close to the β7 strand of the B-loop of a chimera comprising of the human α7 nAChR and the acetylcholine binding protein from Lymnaea stagnalis. This may inhibit the required movement of the C-loop for channel opening, due to steric hindrance, providing a structural mechanism for its antagonist effect. Finally, we have shown that, in α7 nAChR full knockout mice, the behavioral response to D-AMPH is attenuated, providing direct evidence for the role of α7 nAChRs on the physiological response to D-AMPH. Importantly, D-AMPH exerts these effects at concentrations predicted to be pharmacologically relevant for chronic methamphetamine users and during binges. In conclusion, our data present new findings that implicate the α7 nAChR on the pharmacodynamics of ATS, which may be important for behavioral responses to these drugs, indicating a potential role for α7 nAChRs in ATS substance-use disorders.
Abreo,
Novel 3-Pyridyl ethers with subnanomolar affinity for central neuronal nicotinic acetylcholine receptors.
1996, Pubmed
Abreo,
Novel 3-Pyridyl ethers with subnanomolar affinity for central neuronal nicotinic acetylcholine receptors.
1996,
Pubmed
Alkondon,
Diversity of nicotinic acetylcholine receptors in rat hippocampal neurons. I. Pharmacological and functional evidence for distinct structural subtypes.
1993,
Pubmed
Amiri,
Molecular dynamics studies of AChBP with nicotine and carbamylcholine: the role of water in the binding pocket.
2007,
Pubmed
Avale,
Interplay of beta2* nicotinic receptors and dopamine pathways in the control of spontaneous locomotion.
2008,
Pubmed
Baker,
Intermittent nicotine exposure upregulates nAChRs in VTA dopamine neurons and sensitises locomotor responding to the drug.
2013,
Pubmed
Balster,
A comparison of d-amphetamine, l-amphetamine, and methamphetamine self-administration in rhesus monkeys.
1973,
Pubmed
Beers,
Structure and activity of acetylcholine.
1970,
Pubmed
Brams,
A structural and mutagenic blueprint for molecular recognition of strychnine and d-tubocurarine by different cys-loop receptors.
2011,
Pubmed
Brensilver,
Cigarette smoking as a target for potentiating outcomes for methamphetamine abuse treatment.
2013,
Pubmed
Brown,
Nicotine induces the up-regulation of the α7-nicotinic receptor (α7-nAChR) in human squamous cell lung cancer cells via the Sp1/GATA protein pathway.
2013,
Pubmed
Camarasa,
The involvement of nicotinic receptor subtypes in the locomotor activity and analgesia induced by methamphetamine in mice.
2009,
Pubmed
Cao,
Advances and challenges in pharmacotherapeutics for amphetamine-type stimulants addiction.
2016,
Pubmed
Celie,
Nicotine and carbamylcholine binding to nicotinic acetylcholine receptors as studied in AChBP crystal structures.
2004,
Pubmed
Changeux,
Nicotine addiction and nicotinic receptors: lessons from genetically modified mice.
2010,
Pubmed
Chefer,
Overview of brain microdialysis.
2009,
Pubmed
Chipana,
Different oxidative profile and nicotinic receptor interaction of amphetamine and 3,4-methylenedioxy-methamphetamine.
2008,
Pubmed
Colón-Sáez,
The α7 nicotinic acetylcholine receptor function in hippocampal neurons is regulated by the lipid composition of the plasma membrane.
2011,
Pubmed
Copeland,
A comparison of the binding of nicotine and nornicotine stereoisomers to nicotinic binding sites in rat brain cortex.
1991,
Pubmed
Davies,
Characterisation of the binding of [3H]methyllycaconitine: a new radioligand for labelling alpha 7-type neuronal nicotinic acetylcholine receptors.
1999,
Pubmed
Drenan,
Cholinergic modulation of locomotion and striatal dopamine release is mediated by alpha6alpha4* nicotinic acetylcholine receptors.
2010,
Pubmed
Elkashef,
Bupropion for the treatment of methamphetamine dependence.
2008,
Pubmed
Fuller,
Disposition and behavioral effects of amphetamine and , -difluoroamphetamine in mice.
1972,
Pubmed
Gao,
Curariform antagonists bind in different orientations to acetylcholine-binding protein.
2003,
Pubmed
Glennon,
Central nicotinic receptor ligands and pharmacophores.
2000,
Pubmed
Gnegy,
Intracellular Ca2+ regulates amphetamine-induced dopamine efflux and currents mediated by the human dopamine transporter.
2004,
Pubmed
Guo,
Regulation of nicotinic acetylcholine receptor desensitization by Ca2+.
2007,
Pubmed
Gustavsen,
Impairment related to blood amphetamine and/or methamphetamine concentrations in suspected drugged drivers.
2006,
Pubmed
Hall,
A comparison of amphetamine- and methamphetamine-induced locomotor activity in rats: evidence for qualitative differences in behavior.
2008,
Pubmed
Harris,
The bioavailability of intranasal and smoked methamphetamine.
2003,
Pubmed
Huganir,
Phosphorylation of the nicotinic acetylcholine receptor regulates its rate of desensitization.
,
Pubmed
Hutchaleelaha,
Disposition kinetics of d- and l-amphetamine following intravenous administration of racemic amphetamine to rats.
1994,
Pubmed
Hénault,
The role of the M4 lipid-sensor in the folding, trafficking, and allosteric modulation of nicotinic acetylcholine receptors.
2015,
Pubmed
Lamb,
Human d-amphetamine drug discrimination: methamphetamine and hydromorphone.
1994,
Pubmed
Law,
A gating mechanism proposed from a simulation of a human alpha7 nicotinic acetylcholine receptor.
2005,
Pubmed
Li,
Ligand-binding domain of an α7-nicotinic receptor chimera and its complex with agonist.
2011,
Pubmed
Liu,
Amphetamine enhances Ca2+ entry and catecholamine release via nicotinic receptor activation in bovine adrenal chromaffin cells.
2003,
Pubmed
Lopez-Hernandez,
Partial agonist and neuromodulatory activity of S 24795 for alpha7 nAChR responses of hippocampal interneurons.
2007,
Pubmed
,
Xenbase
Melega,
Methamphetamine blood concentrations in human abusers: application to pharmacokinetic modeling.
2007,
Pubmed
Melega,
Pharmacokinetic and pharmacodynamic analysis of the actions of D-amphetamine and D-methamphetamine on the dopamine terminal.
1995,
Pubmed
Mogg,
Methyllycaconitine is a potent antagonist of alpha-conotoxin-MII-sensitive presynaptic nicotinic acetylcholine receptors in rat striatum.
2002,
Pubmed
Musso,
Synthesis and evaluation of the antidepressant activity of the enantiomers of bupropion.
1993,
Pubmed
Palma,
Neuronal nicotinic alpha 7 receptor expressed in Xenopus oocytes presents five putative binding sites for methyllycaconitine.
1996,
Pubmed
,
Xenbase
Paylor,
Alpha7 nicotinic receptor subunits are not necessary for hippocampal-dependent learning or sensorimotor gating: a behavioral characterization of Acra7-deficient mice.
1998,
Pubmed
Peng,
Chronic nicotine treatment up-regulates alpha3 and alpha7 acetylcholine receptor subtypes expressed by the human neuroblastoma cell line SH-SY5Y.
1997,
Pubmed
Pereira,
Alpha-conotoxin-ImI: a competitive antagonist at alpha-bungarotoxin-sensitive neuronal nicotinic receptors in hippocampal neurons.
1996,
Pubmed
Salas,
Decreased withdrawal symptoms but normal tolerance to nicotine in mice null for the alpha7 nicotinic acetylcholine receptor subunit.
2007,
Pubmed
Sharp,
A direct comparison of amphetamine-induced behaviours and regional brain dopamine release in the rat using intracerebral dialysis.
1987,
Pubmed
Sheridan,
The ensemble approach to distance geometry: application to the nicotinic pharmacophore.
1986,
Pubmed
Siciliano,
Biphasic mechanisms of amphetamine action at the dopamine terminal.
2014,
Pubmed
Sitte,
Amphetamines, new psychoactive drugs and the monoamine transporter cycle.
2015,
Pubmed
Slemmer,
Bupropion is a nicotinic antagonist.
2000,
Pubmed
Spitzmaul,
Amphetamine acts as a channel blocker of the acetylcholine receptor.
1999,
Pubmed
Sulzer,
Mechanisms of neurotransmitter release by amphetamines: a review.
2005,
Pubmed
Tallóczy,
Methamphetamine inhibits antigen processing, presentation, and phagocytosis.
2008,
Pubmed
Turowski,
The blood-brain barrier and methamphetamine: open sesame?
2015,
Pubmed
Unwin,
Gating movement of acetylcholine receptor caught by plunge-freezing.
2012,
Pubmed
Vanderheyden,
Distinction between surmountable and insurmountable selective AT1 receptor antagonists by use of CHO-K1 cells expressing human angiotensin II AT1 receptors.
1999,
Pubmed
Verrico,
Safety and efficacy of varenicline to reduce positive subjective effects produced by methamphetamine in methamphetamine-dependent volunteers.
2014,
Pubmed
Winters,
Current advances in the treatment of adolescent drug use.
2014,
Pubmed
de Kloe,
Surface plasmon resonance biosensor based fragment screening using acetylcholine binding protein identifies ligand efficiency hot spots (LE hot spots) by deconstruction of nicotinic acetylcholine receptor α7 ligands.
2010,
Pubmed